Mazariegos, M, Girones, R, Del Barco, S, Garcia, A, Velilla, G, Hernandez, A, Alonso, M, Ferreira, L, Luque, N, Fernández,, Quintanar, T, Peralta, S, Ceballos,, Iza, E, Sanchez, M, Martín, EP, Casado, EA, Mazarico, J, Duran, G, Alvarez, P, Ayala, P, Gallego, O, Sarabia, R, de las Penas, R, Nuñez,, Morilla,, Cunquero, A, Cheverria, N, Moya,, Vaz, M, Luque, R, Esteve, A, Pineda, E. P25.03.B RWD OF IDH MUTANT GLIOMAS IN SPAIN, A RETSINE - GEINO STUDY. NEURO-ONCOLOGY. 2024; 26DOI:10.1093/neuonc/noae144.446. PMID:. IF:13.400(Q1/1D).

Vidal, N, Climent, MA, Pérez, S, Méndez-Vidal, MJ, Anguera, G, Salas, IM, Gallardo, E, Cuéllar-Rivas, MA, Molina-Cerrillo, J, Martín, A, Rodriguez-Vida, A, Casado, EA, Gonzalez, M, Domènech, M, Kareaga, MM, Calvo, OF, Guzmán, JCV, Estévez, SV, Gonzàlez-del-Alba, A, Puente, J. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study. Clinical & Translational Oncology. 2024; DOI:10.1007/s12094-024-03744-6. PMID:39369361. IF:2.500(Q3/6D).

Bellmunt, J, Maroto, P, Bonfill, T, Vazquez, F, Perez-Gracia, JL, Juanpere, N, Hernandez-Prat, A, Hernandez-Llodra, S, Rovira, A, Juan, OS, Rodriguez-Vida, A. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study. Clinical Genitourinary Cancer. 2024; 22(5)DOI:10.1016/j.clgc.2024.102123. PMID:38905731. IF:2.700(Q2/3D).

Abu Remilah, A, Krayim, B, Amir, E, Tibau, A, Robson, ME, Abuhadra, N, Chen, Y, Shepshelovich, D, Goldvaser, H. The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2024; 202DOI:10.1016/j.critrevonc.2024.104455. PMID:39067779. IF:5.600(Q1/2D).

Waterhouse, DM, Rothschild, S, Dooms, C, Mennecier, B, Bozorgmehr, F, Majem, M, Heuvel, MHV, Linardou, H, Cho, BC, Roberts-Thomson, R, Tanaka, K, Blais, N, Schvartsman, G, Hansen, KH, Chmielewska, I, Forster, MD, Giannopoulou, C, Stollenwerk, B, Obiozor, CC, Wang, Y, Novello, S. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. LUNG CANCER. 2024; 196DOI:10.1016/j.lungcan.2024.107921. PMID:39303400. IF:4.400(Q1/2D).

de Castro, J, Dols, MC, Gómez, MD, Vega, AM, Aix, SP, Arriola, E, Carcereny, E, Majem, M, Vence, GH, González, EE, Pradera, JF, Granados, ALO, Morales, MG, Sureda, BM, Núñez, NF, Provencio, M, González-Mancha, N, Fajardo, CA, Lerones, N, Campelo, RG. Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Jones, DR, Wakelee, H, Spicer, JD, Liberman, M, Kato, T, Tsuboi, M, Lee, SH, Wang, W, Chen, H, Dooms, C, Majem, M, Eigendorff, E, Martinengo, GL, Bylicki, O, Huang, HC, Novello, S, Jensen, E, Keller, SM, Samkari, A, Kalhor, N. Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Majem, M, Sullivan, IG, Torrego, A, Surrallés, J, Purdy, J, Carmona, MA, Dunsford, H, Wubs, M. An Evidence-Driven Approach to Optimizing Clinical, Operational, And Economic Value in the Lung Cancer Care Pathway. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).